JOAQUÍN
DÍAZ MEDIAVILLA
Researcher to 2014
Felipe de
Arriba de la Fuente
Publications by the researcher in collaboration with Felipe de Arriba de la Fuente (10)
2013
-
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control
Leukemia, Vol. 27, Núm. 10, pp. 2056-2061
-
Erratum: A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control (Leukemia (2013) 27 (2112))
Leukemia
2012
-
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Blood, Vol. 119, Núm. 3, pp. 687-691
-
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials
American Journal of Pathology, Vol. 181, Núm. 5, pp. 1870-1878
-
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study
Blood, Vol. 120, Núm. 8, pp. 1589-1596
2011
-
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
Blood, Vol. 118, Núm. 17, pp. 4547-4553
2010
2008
-
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
Blood, Vol. 112, Núm. 9, pp. 3591-3593
-
Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy
Journal of Clinical Oncology, Vol. 26, Núm. 16, pp. 2737-2744
2006
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study
Blood, Vol. 108, Núm. 7, pp. 2165-2172